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intensive care units (ICUs) using the checklist. Setting: Online survey software was used for checklist 
development. The prospective audit using the checklist was conducted in 10 ICUs in Australia and New 
Zealand. Participants: Checklist development was conducted with members of a bi-national professional 
society for critical care physicians using a modified Delphi technique and survey. A 30-day audit of adult 
patients mechanically ventilated for >72 h. Primary and secondary outcome measures: Presence of items 
on the screening checklist; physician diagnosis of VAP, clinical characteristics, investigations, treatments 
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sputum changes, chest X-ray infiltrates, inflammatory response, microbial growth. Of the 169 participants, 
17% (n=29) demonstrated characteristics of VAP using the checklist. A similar proportion had an 
independent physician diagnosis (n=30), but in a different patient subset (only 17% of cases were 
identified by both methods). The VAP rate per 1000 mechanical ventilator days for the checklist and 
clinician diagnosis was 25.9 and 26.7, respectively. The item 'inflammatory response' was most 
associated with the first episode of physician-diagnosed VAP. Conclusions: VAP rates using the checklist 
and physician diagnosis were similar to ranges reported internationally and in Australia. Of note, different 
patients were identified with VAP by the checklist and physicians. While the checklist items may assist in 
identifying patients at risk of developing VAP, and demonstrates synergy with the recently developed 
Centers for Disease Control (CDC) guidelines, decisionmaking processes by physicians when diagnosing 
VAP requires further exploration. 
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ABSTRACT
Objectives: With disagreements on diagnostic criteria
for ventilator-associated pneumonia (VAP) hampering
efforts to monitor incidence and implement
preventative strategies, the study objectives were to
develop a checklist for clinical surveillance of VAP, and
conduct an audit in Australian/New Zealand intensive
care units (ICUs) using the checklist.
Setting: Online survey software was used for checklist
development. The prospective audit using the checklist
was conducted in 10 ICUs in Australia and New Zealand.
Participants: Checklist development was conducted
with members of a bi-national professional society for
critical care physicians using a modified Delphi
technique and survey. A 30-day audit of adult patients
mechanically ventilated for >72 h.
Primary and secondary outcome measures:
Presence of items on the screening checklist; physician
diagnosis of VAP, clinical characteristics, investigations,
treatments and patient outcome.
Results: AVAP checklist was developed with five items:
decreasing gas exchange, sputum changes, chest X-ray
infiltrates, inflammatory response, microbial growth.
Of the 169 participants, 17% (n=29) demonstrated
characteristics of VAP using the checklist. A similar
proportion had an independent physician diagnosis
(n=30), but in a different patient subset (only 17% of
cases were identified by both methods). The VAP rate
per 1000 mechanical ventilator days for the checklist
and clinician diagnosis was 25.9 and 26.7, respectively.
The item ‘inflammatory response’ was most associated
with the first episode of physician-diagnosed VAP.
Conclusions: VAP rates using the checklist and
physician diagnosis were similar to ranges reported
internationally and in Australia. Of note, different
patients were identified with VAP by the checklist and
physicians. While the checklist items may assist in
identifying patients at risk of developing VAP, and
demonstrates synergy with the recently developed
Centers for Disease Control (CDC) guidelines, decision-
making processes by physicians when diagnosing VAP
requires further exploration.
INTRODUCTION
Treatment of critically ill patients commonly
includes invasive mechanical ventilation
(MV) in an intensive care unit (ICU).
Iatrogenic lung injury, including ventilator-
associated pneumonia (VAP), is a risk influ-
enced by severity of illness, immune func-
tion, physiological reserve and duration of
invasive ventilation.1 2 Patients diagnosed
with VAP have a longer ICU length of stay
(LOS), 3 higher mortality rates4 and higher
costs of treatment.3
The reported rate of VAP in North
American and European ICU settings is 1–53
Strengths and limitations of this study
▪ The ventilator-associated pneumonia (VAP)
checklist was developed by consensus with
members of a bi-national professional organisa-
tion of intensive care physicians.
▪ The checklist was tested in a multisite prospect-
ive 30-day audit, demonstrating feasibility of data
collection and external validity for calculating a
contemporary VAP rate for intensive care units in
Australia and New Zealand.
▪ Cases identified via the screening checklist dif-
fered from independent physician diagnosis of
VAP, and microbiological analysis of pulmonary
secretions, the gold standard for diagnosing
VAP, was not part of the study’s scope because
of funding constraints.
▪ Other patient characteristics physicians used to
diagnose VAP remains unknown, and further
investigation is required to produce an accept-
able surveillance definition for use in routine
practice.
▪ Checklist items align with the revised surveil-
lance approach from the US’ Centers for Disease
Control and National Health Safety Network.
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cases per 1000 ventilator days,3 5–7 affecting up to 30%
of patients receiving MV.6 While current definitions
exist,2 8–10 lack of accuracy and reliability in measure-
ment remains a challenge for diagnosis.11–15 This is
reflected in lack of consensus about the diagnosis of
VAP in Australia and New Zealand,16 with few healthcare
facilities routinely collecting VAP data.17 While a 2005
study across 14 ICUs revealed a rate of 28%,18 bi-national
rates are currently unknown. Effective and systematic
VAP prevention strategies are limited by this lack of
consensus.
The study objectives were to develop and test a check-
list for clinical surveillance of VAP; and conduct an audit
in a sample of ICUs using the checklist to measure the
current rate of VAP.
METHODS
A dual-method study design was used, involving a modi-
fied Delphi technique to construct the VAP checklist
items; and a multisite prospective audit conducted in 10
ICUs across Australia (n=9) and New Zealand (n=1).
Our decision on the sample size was pragmatic, based
on similar previous Australasian studies,18 piloting the
time required for data collection, and the funding avail-
able to support site-based data screening and daily data
collection for 1 month across the sites. The University’s
Human Research Ethics Committee approved the
Delphi study. For the audit phase, ethics and local clin-
ical governance approval was obtained from the Human
Research Ethics Committees of a lead clinical site, each
of the participating sites, and then ratified by the
University Committee. The need for individual informed
patient consent was waived by the lead site Committee,
as the study was deemed low risk.
Checklist development
A list of clinical characteristics of VAP was initially devel-
oped from a survey constructed using current studies,
including previously published criteria for VAP.19–21
A draft survey was sent to the Quality and Safety (Q&S)
Committee of the Australian and New Zealand
Intensive Care Society (ANZICS), who reviewed the
items as experts for face validity, and recommended
minor changes. This revised version was then distribu-
ted to all ANZICS members using SurveyMonkey (Palo
Alto, California, USA; December 2012 and January
2013).
Respondents were requested to rate their agreement
on a four-point Likert scale for each criterion, provide
comment and list any other diagnostic criteria they used.
Item concordance was set at >80% agree/agree strongly.
Content analysis was conducted on free-text fields for
two items on standardised VAP criteria and incorporated
into items. Validity of the results was checked during
team discussions, and members of the ANZICS Q&S
Committee reviewed the second draft for face validity.
The checklist was then pilot tested at a volunteer site
and further refinements made for the final version (see
online supplementary additional file 1).
Prospective audit
Sites were invited to participate by the ANZICS executive
via email; of 15 expressions of interest received 10 were
selected based on level of service and geographical loca-
tion;22 we estimated that an audit of this sample size
over a 30-day period would provide an accurate estimate
of VAP rates binationally.15 18 22 23
Data collection
A 28-item case report form (CRF) was developed,
incorporating the VAP checklist and data on clinical
characteristics, and patient demographics (see online
supplementary additional file 2). Site-based research
coordinators were trained in completion of the checklist
and related CRF and data dictionary prior to data collec-
tion. Site investigators screened for eligible patients
daily, using the following inclusion criteria: ICU patients
>16 years old, invasively mechanically ventilated for
>72 h, with no treatment limitation orders. Data collec-
tion started for study participants after 72 h of MV. Data
were collected prospectively for all enrolled patients
until ICU discharge or end of data collection (8 July—2
August 2013). Independent physician diagnosis of VAP
was identified from patient medical records to enable
comparisons with the checklist.
Statistical analyses
Patient characteristics were compared for those who had
VAP reported according to the checklist or physician
diagnosis, and those who had not. Analyses were by inde-
pendent t tests or Wilcoxon rank-sum tests for continu-
ous data and Fisher’s exact tests for categorical data. A
total VAP checklist score was calculated as the sum of
each of the items (each item scoring ‘1’; range 0–5).
The VAP rate was calculated as: VAP reported or diag-
nosed/total number of ventilator days×1000 for enrolled
patients, and reported for: the number of patients posi-
tive for four (items 1–4) or all five checklist items; and
the number of patients independently diagnosed with
VAP by physicians.
A generalised estimating equation (GEE) model,
using a logit function with an exchangeable correlation
structure (conceptualised as an extension of logistic
regression models with repeated measures analysed lon-
gitudinally24), enabled investigation of relationships
between positive reports of items in the checklist (inde-
pendent variables) and physician diagnosis (dependent
variable) over time.
RESULTS
Checklist development
The survey response rate for ANZICS members was 16%
(n=79/485). Most respondents (78%) worked in a
tertiary-level ICU (College of Intensive Care Medicine
2 Elliott D, et al. BMJ Open 2015;5:e008924. doi:10.1136/bmjopen-2015-008924
Open Access
copyright.
 o
n
 M
arch 15, 2020 at University of W
ollongong. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-008924 on 29 October 2015. Downloaded from 
(CICM) level III).25 Years of experience since obtaining
their specialty qualification was approximately 25% each
for <5, 6–10, 11–20 and >20 years. One-third indicated
that VAP was monitored in their ICU, and 14% reported
using standardised criteria for diagnosis. There was a
>80% ‘agree/strongly agree’ rating for several items
comprising published standardised criterion for VAP
diagnosis (including statements related to gas exchange,
respiratory secretion characteristics and radiological
changes). The final consensus-developed VAP checklist
is noted in table 1, with the five items listed in order
from least to more invasive assessments.
Multisite audit
ICU and patient characteristics
The study units, all located in public hospitals, included
seven tertiary referral (level III), one level II and two
level I ICUs.25 The contribution of patients from each
participating site and ICU bed numbers are illustrated
in figure 1. The units ranged in size from 14 to 58 beds,
and were located in five jurisdictions across Australia
and one in New Zealand. Study ICUs represented 20%
(7/35) of the tertiary units binationally.26 Some units
reported policies related to minimising or preventing
VAP: seven practised a policy of ensuring patients were
positioned with the head of the bed elevated >45° most
of the time; four routinely used subglottic suction endo-
tracheal/tracheostomy tubes; and five indicated that
mouth care with chlorhexidine (any concentration) was
routine practice. One unit reported the use of all three
preventative measures.
A final sample of 169 patients mechanically ventilated
for >72 h were enrolled from initial screening of 345.
Data were collected for 1692 bed-days during the study
period, including 1122 days when patients received
>12 h of MV per day. The contribution of patients from
each participating site and ICU bed numbers are illu-
strated in figure 1. Mean participant age was 59.7 years,
65% were male and 64% were admitted with a medical
diagnosis (25% had either a cardiac or respiratory diag-
nosis). The median durations for MV and ICU LOS were
7 and 11 days, respectively (see table 2).
Patients screened or diagnosed with VAP
All five characteristics of VAP from the screening check-
list were reported in only 10 patients. Given the low inci-
dence of actual laboratory assessments performed for
sputum growth (discussed in later section), exclusion of
item 5 resulted in 29 patients screened as having VAP
(17.2% of sample). The VAP rate for checklist items 1–4
was 25.9 per 1000 mechanical ventilator days (8.9 when
all 5 items were present). Checklist items with the
highest number of positive reports were: arterial oxygen
tension (PaO2) to fraction of inspired oxygen (FiO2)
ratio (PF ratio; item 1; n=855), ‘inflammatory response’
(item 4; n=793) and ‘sputum changes’ (item 2; n=306).
The most commonly reported subitem within ‘inflam-
matory response’ was ‘white cell count ≤4 or ≥12 cells
109/L for 2 days’ (n=552). As noted in table 2, patients
identified with VAP using the checklist were more likely
to be male (p=0.05), ventilated for ≥4 days (p=0.002),
had an ICU LOS 5 days longer than those patients with
no checklist items present and have a primary non-
operative trauma diagnosis (p=0.05).
Treating physicians independently clinically diagnosed
30 patients with VAP (documented in patient records;
17.8% of sample), reflecting a slightly higher VAP rate
of 26.7 per 1000 mechanical ventilator days. Patients
with a physician diagnosis of VAP had similar character-
istics—MV 2.5 days longer (p=0.04) and an ICU LOS
3 days longer than those patients with no physician VAP
diagnosis (p=0.03). A higher proportion of patients with
a non-operative cardiac diagnosis were subsequently
diagnosed with VAP (p=0.05), while few patients with a
non-operative respiratory diagnosis developed VAP from
either group.
Table 1 VAP checklist items
Item Definition
1 PaO2/FiO2 ratio*
≤300 mm Hg
Deterioration in gas exchange over past 24 h in the absence of cardiogenic pulmonary oedema
or pulmonary disease
2 Sputum changes A change in sputum characteristics, increased volume or colour changes (yellow or green)
3 CXR infiltrates New localised or diffuse infiltrates on a single CXR (not explained by cardiogenic pulmonary
oedema or pulmonary disease)
4 Inflammatory response ≥1 of the following (in the absence of immunocompromise)
A.↑ Temperature New and persistent (past 24 h) elevated body temperature ≥38°C (or >37.5°C if concurrent
antipyretic medication administration)
B.WCC WCC ≤4 or ≥12 cells 109/L for 2 days
C.↑ Inflammation Elevated serum inflammatory markers: C reactive protein (>100 mg/L) or procalcitonin
(>2.5 ng/L) for a single blood test
5 Microbial growth Microbial growth in tracheal secretions obtained by tracheal suctioning or bronchoscopy
(ie, >25 neutrophils per low power field or equivalent)
Three days after a patient is started on mechanical ventilation, are any of the following clinical characteristics present?
*PaO2/FiO2 ratio=arterial oxygen tension/fraction of inspired oxygen.
CXR, chest X-ray; VAP, ventilator-associated pneumonia; WCC, white cell count.
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Of note, however, only five patients (17%) had
documented VAP using both the screening checklist
(4 items) and physician diagnosis. These patients
(4 male: 1 female) had a moderate-to-high severity of
illness score (APACHE II score range 12–23), received
MV for 11–27 days and were treated in ICU for
13–57 days. Three patients had documented VAP using
all five checklist items and physician diagnosis.
An unadjusted OR for ‘inflammatory response’ (item
4) of 3.88 was noted when examining associations
between the checklist items and physician diagnosis;
patients with a positive recording had a fourfold
increase in the risk of receiving a physician diagnosis of
VAP compared with patients who did not have a positive
report. ORs for other items were not statistically signifi-
cant (range 1.27–2.07; see table 3).
Post hoc analyses between checklist or physician diag-
nosis of VAP and microbial growth (infected or colo-
nised sputum) provided no significant associations, with
the small number of identified VAP cases who received
microbiological sputum reports precluding further ana-
lyses (see online supplementary additional file 3 for
further details). In relation to administration of antimi-
crobials, descriptive analyses revealed a higher propor-
tion of patients with a physician diagnosis of VAP (83%)
received antimicrobials compared with patients identi-
fied using the VAP four-item checklist (72%). See online
supplementary additional file 3 for proportions and
details reported for each case group. No further analyses
were preformed because of the small sample size and
the overlap between checklist and physician cases (n=5).
DISCUSSION
Key findings compared with previous studies
Study participants had a longer ICU LOS, and higher
severity of illness scores and mortality rates compared
with all mechanically ventilated patients, but a lower
median length of MV (7 vs 11 days) and ICU LOS (11 vs
30 days) when compared with patients receiving MV for
>3 days in Australian and New Zealand ICUs.26
A VAP incidence of 17% of patients for the checklist
was within the range frequently reported in the inter-
national literature (9–27%),27 but lower than other
reports (29%28; 30%6; 38%29) including from Australia
(28%).18 This may be explained in part by the inclusion
criteria, with patients who received short-term ventila-
tion excluded, and enrolment of patients with an
extended ICU LOS, an associated higher mean APACHE
II score (20 vs 14) and higher mortality rate (23% vs
10%).22 It is also possible that misdiagnosis was respon-
sible for some VAP reports, and the ‘true’ rate may be
lower (three patients with a clinician diagnosis of VAP
had cardiogenic shock and one had aspiration pneumo-
nia). ‘Overlapping diagnoses’ confounding VAP rates
has been previously reported.30
Little overlap between the patients identified by check-
list and physician diagnosis was unexpected. This dis-
crepancy may reflect continued lack of agreement in the
Australian and New Zealand intensive care community,
between what intensive care physicians think should
happen (policy and guidelines) and what happens in
actual practice, and reinforces a continued need for an
agreed surveillance definition.
The only checklist item associated with a physician
diagnosis of VAP was ‘inflammatory response’, reflecting
a fourfold increase in the risk of receiving an physician
diagnosis of VAP compared with patients without a
noted inflammatory response. This finding may reflect
the evolving contemporary view of VAP as one element
in a continuum of airway changes including inflamma-
tion.31 The absence of any other item associated with a
VAP physician diagnosis may have been a result of small
sample sizes for other items. New infiltrates on chest
Figure 1 Contributions of
participating sites: number of
intensive care unit (ICU) beds
and patients enrolled (College of
Intensive Care Medicine (CICM)
level25).
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X-ray was found by others to be highly indicative of a
diagnosis of pneumonia27 but was not the case in our
study. Two possible explanations are evident: ‘overlap-
ping diagnoses’ (eg, acute lung injury), and the under-
reporting of chest X-ray changes in patient records.
Note also that we used physician diagnosis as a prag-
matic comparator reflecting routine practice.
‘Microbial growth in tracheal secretions’ (item 5) did
not contribute to the explanatory model, perhaps
because of low documented laboratory reports, and pos-
sible collinearity with ‘change in sputum characteristics’
(item 2). Pathology services at study sites contacted prior
to the audit confirmed that a quantitative report for the
presence of white cells in sputum was routine microbiol-
ogy reporting. However, in practice, many site investiga-
tors reported that their organisation’s pathology services
did not provide this. In the absence of a pathology
report, site data collectors responded ‘no’ to this item.
Arguably, presence of ‘sputum changes’ is a visual cue for
microbial/white cell debris, and likely to manifest in a
quantitative report of ‘>25 neutrophils per low power
field or equivalent’ in sputum obtained by tracheal suc-
tioning. Neither item however contributed significantly
to the GEE model (ORs 1.27 and 1.52, respectively).
Study strengths and limitations
Our approach to data collection was comprehensive but
feasible; the latter important for quality indicator data to
be collected sustainably. Our VAP rate (17%) using
checklist items 1–4 was in ranges reported in the inter-
national literature, suggesting congruence with
approaches used by others. The study sample involved
Table 2 Study patient characteristics, including those screened or diagnosed with VAP
Overall
sample
(n=169)
Screened using VAP checklist
items 1–4 Diagnosed by an intensivist
Characteristic VAP (n=29)
No VAP
(n=140) p Value VAP (n=30)
No VAP
(n=139) p Value
Age, mean±SD (years) 59.71±15.98 59.78±17.03 59.71±15.83 0.98* 58.60±18.63 59.95±15.72 0.67*
Gender, n (%) (male) 110 (65) 22 (76) 88 (63) 0.05† 21 (70) 89 (64) 0.53†
BMI, mean±SD 28.79±7.28 28.95±7.21 28.75±7.32 0.90* 28.28±7.01 28.90±7.36 0.69*
APACHE II score, mean±SD 20.61±7.08 18.76±6.30 21.01±7.19 0.09* 18.63±4.60 21.04±7.45 0.09*
Charlson, median (IQR) 1 (0–2) 1 (0–2) 1 (0–2) 0.23‡ 1 (0–2) 1 (0–2) 0.23‡
Smoking, median (IQR),
(years)
0 (0–10) 0 (0–6) 0 (0–13.5) 0.55‡ 0 (0–10) 0 (0–12) 0.71‡
Smoking, dichotomised, n (%) – 8 (27) 45 (28) 0.62† 9 (30) 44 (31) 0.86†
ED admission, n (%) 38 (22) 8 (27) 30 (21) 0.47§,¶ 7 (23) 31 (22) 0.71§,¶
Readmission ICU, n (%) 15 (9) 4 (14) 11 (8) 0.31§ 1 (3) 14 (10) 0.47§
Mechanical ventilation, median
(IQR) (chart days)
7 (5–12) 11 (7–16) 7 (5–11) 0.002 9.50 (7–14) 7 (5–12) 0.04
ICU LOS, median (IQR) (days) 11 (8–19) 15 (10–22) 10 (7–17) 0.01 13 (10–20) 10 (7–17) 0.03
Hospital LOS, median (IQR)
(days)
30 (16–43) 29 (20–49) 24 (14–40.5) 0.11 26 (17–48) 25 (15–41) 0.92
Alive at 30 days, n (%) 131 (77) 24 (83) 107 (75) 0.46† 21 (70) 110 (79) 0.27†
Non-operative diagnosis, n (%) 108 (64) 22 (76) 86 (61) 0.13† 18 (60) 90 (65) 0.62†
Cardiac, n (%) 25 (23) 5 (17.5) 20 (14) 0.41 8 (27) 17 (12) 0.05
Respiratory, n (%) 28 (26) 4 (14) 24 (17) 0.45 1 (3) 27 (19) 0.01
Gastrointestinal, n (%) 9 (8) 0 9 (6.5) 0.17 2 (7) 7 (5) 0.50
Neurological, n (%) 10 (9) 2 (7) 8 (6) 0.54 3 (10) 7 (5) 0.50
Sepsis, n (%) 14 (13) 4 (14) 10 (7) 0.20 0 14 (10) 0.60
Trauma, n (%) 13 (12) 5 (17.5) 8 (6) 0.05 4 (13) 9 (7) 0.18
Other, n (%) 9 (8) 2 (7) 7 (5) 0.47 0 9 (7) 0.15
Operative diagnosis, n (%) 61 (36) 7 (24) 54 (39) 0.13† 12 (40) 49 (35) 0.62†
Cardiac, n (%) 29 (47) 4 (14) 25 (18) 0.41 6 (20) 23 (17) 0.41
Respiratory, n (%) 0 0 0 – 0 0 –
Gastrointestinal, n (%) 10 (16) 1 (3) 9 (6.5) 0.46 0 10 (7) 0.13
Neurological, n (%) 10 (16) 1 (3) 9 (6.5) 0.46 4 (13) 6 (4) 0.08
Trauma, n (%) 10 (16) 1 (3) 9 (6.5) 0.46 2 (7) 8 (6) 0.56
Other, n (%) 2 (5) 0 2 (1) 0.68 0 2 (1) 0.68
*Independent t test (unequal variances) two tailed.
†χ2 Test.
‡Wilcoxon rank-sum (Mann-Whitney) test.
§Fishers exact test (one-sided).
¶Analysis included comparisons for all locations of patients prior to ICU admission.
APACHE, Acute Physiology and Chronic Health Evaluation (on admission); BMI, body mass index (height and weight available for n=145);
ED, emergency department; ICU, intensive care unit; LOS, length of stay; VAP, ventilator-associated pneumonia.
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differing levels of ICU conferring potential external val-
idity. A sample size of 10 ICUs was however small, with
any representativeness to the Australian and New
Zealand context probably confined to tertiary-level units;
note also that only New Zealand ICU was involved.
Examination of longitudinal relationships between phys-
ician diagnosis and checklist items over time enabled
insight into the contribution of each item, and a quanti-
tative measure of the increased possibility of a diagnosis
of VAP in the presence of an inflammatory response.
Independence between checklist data collected by site-
based investigators and diagnosis of VAP by independent
physicians was both a study strength and weakness.
Assessment using the checklist was unbiased, but the
decision-making process for a physician diagnosis was
not documented and remains unknown. Use of phys-
ician diagnosis as a comparator was therefore a limita-
tion as individual physicians appeared to use a different
set of criteria to diagnose VAP. Given the disparate cases
identified between the checklist and physicians, it would
have been useful to incorporate in the methods a review
of case notes by an independent panel of clinicians for
verification of likely VAP diagnosis, whether the clinical
course reflected pneumonia, and to identify any predic-
tors and patterns in antibiotic prescription. Other infor-
mation, such as findings from thoracic CT scans or
autopsy results, would also have been useful, but were
not abstracted a priori from patient notes.
Our study was not funded for microbiological analysis
of pulmonary secretion11 on all screened patients.
Independent microbial analyses were used when avail-
able through routine practice, but were not a require-
ment for study inclusion, and were only reported in 7%
of patients. This variability in reporting was therefore a
limitation given that this was one of the VAP checklist
items (5, ‘sputum growth’). Our analyses did however
indicate that ‘sputum changes’, item 2, may be a proxy
albeit less sensitive and objective indicator than a formal
microbiological report.
Additional limitations are noted. There may be differ-
ences between physicians who were members of ANZICS
and those who were not. In addition, four-fifths of
respondents worked in tertiary-level ICUs. We are there-
fore unsure whether our sample was truly representative
of intensive care physicians practising across Australia
and New Zealand. There was evidence of local unit
consensus when completing the survey, so it appears
likely that input from intensivists was higher than 16%.
(Attempts were made to increase survey participation.)
Communications from intensivists indicated that some
ICU directors nominated a spokesperson to complete
the VAP survey. The number of physicians providing
input to the survey therefore probably exceeded 79. This
unintentional unit-level approach may have limited vari-
ability in the full-text responses, and the sampling may
have been biased to physicians who were convinced
about the need for VAP surveillance (75% respondents
agreed that VAP surveillance should be routine) or ICUs
in which VAP monitoring was practised. It appeared that
there were few responses from ‘VAP sceptics’.
Implications for practice
Our consensus-derived checklist items were equivalent
to items from the Clinical Pulmonary Infection Score
(CPIS): temperature, blood leucocytes, tracheal secre-
tions, oxygenation, radiography, tracheal aspirate
culture.20 This outcome may have occurred because the
CPIS instrument was a source document during our
initial modified Delphi survey, and retained as these clin-
ical characteristics resonated with previous training and
contemporary clinical experiences of practising intensive
care physicians.
Checklist items are also similar in content to a revised
surveillance approach from the US Centers for Disease
Control (CDC) and National Health Safety Network
(NHSN).31 An algorithm is used to define a continuum
of: a ventilator-associated condition, infection-related
ventilator-associated complications and possible/prob-
able VAP. A comparison of the features of our VAP
checklist and the CDC/NHSN guidelines are presented
in table 4. This approach formally reconceptualises
inflammatory and infectious processes associated with
an artificial airway and MV as a continuum of ‘events’.31
While initial studies highlighted some methodological
concerns,32 33 recently the new CDC/NHSN approach
demonstrated superior reliability and validity compared
with their former VAP definition, and may enable auto-
mated surveillance.34
Similarities between our definition and the CDC/
NHSN approach and the relative ease with which site
investigators used the VAP checklist suggests that our
consensus-based checklist may be an appropriate
Table 3 VAP checklist items associated with clinician diagnosed VAP: multivariate analysis model (all 5 items)
Item number Item OR 95% CIs p Value
1 PF ratio ≤300 mm Hg (n=855) 1.58 0.61 to 3.99 0.338
2 Sputum changes (n=306) 1.27 0.55 to 2.86 0.566
3 CXR infiltrates (n=143) 2.07 0.82 to 5.19 0.115
4 Inflammatory response (n=793) 3.88 1.38 to 10.98 0.010
5 Microbial growth (n=11) 1.52 0.59 to 3.87 0.375
PF ratio, PaO2/FiO2 ratio.
CXR, chest X-ray; PaO2/FiO2 ratio, arterial oxygen tension/fraction of inspired oxygen; VAP, ventilator-associated pneumonia.
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adjunct for automated surveillance from electronic
medical records in Australia and New Zealand.
Recommendations for further research
Our approach does limit interpretation for some find-
ings; the checklist items demonstrated mixed reliability
and validity, with ‘inflammatory response’ the only item
strongly associated with a clinician diagnosis of VAP.
Given the ORs (but not statistical significance) for other
items, we recommend that the checklist continue to be
evaluated in practice with larger sample sizes and evalu-
ation of patient outcomes to further test its utility as a
screening tool for VAP.
Future work could explore similarities between the
characteristics of patients diagnosed with VAP using both
the checklist and independent physician diagnosis to
refine checklist items. This could potentially increase
the identification of patients that would benefit from
treatment that differentiates a generalised inflammatory
response from an infection.
Importantly, and as noted earlier, we are unclear
about the actual decision-making processes used by clini-
cians. With little overlap in identified patients between
physician diagnosis and the screening checklist, there
are clearly other factors involved during the diagnostic
process. Further exploration of the decision-making
process of individual physicians when considering VAP,
and the rationale for any related antibiotic prescribing is
therefore required.
CONCLUSIONS
This consensus-developed ‘VAP checklist’ with four
items: PF ratio, sputum changes, chest X-ray infiltrates
and inflammatory response, identified 17% of this
sample with characteristics of VAP, reflecting an inci-
dence of 25.9 per 1000 mechanical ventilator days.
Patients identified from independent physician diagnosis
of VAP differed from those using the checklist, and
requires further investigation to enable development of
an acceptable surveillance definition for use in routine
practice.
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Table 4 Comparison of VAP surveillance criteria
Australian and New Zealand-developed checklist items CDC/NHSN-developed three-tiered elements33
1. PaO2/FiO2 ratio ≤300 mm Hg: decreased gas exchange in past 24 h
(no cardiogenic pulmonary oedema/pulmonary disease)
Increased daily FiO2 increases of ≥0.2 or PEEP
values ≥3 cm H2O)=VAC
4. Inflammatory response: ≥1 of the following (when no
immunocompromise)
On or after day 3 of MV and within 2 calendar days
of worsening oxygenation:
A. New/persistent ↑ temperature ≥38°C > 38°C or and new antimicrobials
started=IVACB. WCC ≤4 or ≥12 cells 109/L for 2 days WCC ≤4 or ≥12
109/L
C. Elevated C reactive protein (>100 mg/L) or procalcitonin (>2.5 ng/L) NA
5. Microbial growth: >25 neutrophils per low power field in tracheal
secretions
Purulent respiratory secretions containing >25
neutrophils per low power field=VAP
2. Sputum changes: increased volume, or colour changes (yellow or
green)
NA
3. CXR infiltrates: new localised or diffuse infiltrates on single CXR
(no cardiogenic pulmonary oedema/pulmonary disease)
NA
CXR, chest X-ray; IVAC, infection-related ventilator-associated complication; MV, mechanical ventilation; NA, not applicable; PaO2/FiO2 ratio,
arterial oxygen tension divided by fraction of inspired oxygen; PEEP, positive end-expiratory pressure; VAC, ventilator-associated condition;
VAP, ventilator-associated pneumonia; WCC, white cell count.
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